Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Mcculloch, R. Uddman, T. Kingman, L. Edvinsson (1986)
Calcitonin gene-related peptide: functional role in cerebrovascular regulation.Proceedings of the National Academy of Sciences of the United States of America, 83 15
M. Bigal, D. Dodick, A. Rapoport, S. Silberstein, Yuju Ma, Ronghua Yang, P. Loupe, R. Burstein, L. Newman, R. Lipton (2015)
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b studyThe Lancet Neurology, 14
Christopher Malone, A. Bhowmick, A. Wachholtz (2015)
Migraine: treatments, comorbidities, and quality of life, in the USAJournal of Pain Research, 8
P. Durham, A. Russo (1999)
Regulation of Calcitonin Gene-Related Peptide Secretion by a Serotonergic Antimigraine DrugThe Journal of Neuroscience, 19
A. Recober, A. Russo (2007)
Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment.IDrugs : the investigational drugs journal, 10 8
L. Edvinsson, S. Eftekhari, C. Salvatore, K. Warfvinge (2011)
Cerebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in ratMolecular and Cellular Neuroscience, 46
J. Lennerz, Victor Rühle, E. Ceppa, W. Neuhuber, N. Bunnett, E. Grady, K. Messlinger (2008)
Calcitonin receptor‐like receptor (CLR), receptor activity‐modifying protein 1 (RAMP1), and calcitonin gene‐related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: Differences between peripheral and central CGRP receptor distributionJournal of Comparative Neurology, 507
A. May, L. Schulte (2016)
Chronic migraine: risk factors, mechanisms and treatmentNature Reviews Neurology, 12
J. Cohen, D. Dodick, Ronghua Yang, L. Newman, Thomas Li, E. Aycardi, M. Bigal (2017)
Fremanezumab as Add‐On Treatment for Patients Treated With Other Migraine Preventive MedicinesHeadache: The Journal of Head and Face Pain, 57
S. Eftekhari, C. Salvatore, A. Calamari, S. Kane, J. Tajti, L. Edvinsson (2010)
Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglionNeuroscience, 169
S. Tepper, M. Ashina, U. Reuter, J. Brandes, D. Doležil, S. Silberstein, P. Winner, Dean Leonardi, D. Mikol, R. Lenz (2017)
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trialThe Lancet Neurology, 16
Ann Raddant, A. Russo (2011)
Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulationExpert Reviews in Molecular Medicine, 13
Lars Edvinsson, Ernst Brodin, I. Jansen, R. Uddman (1988)
Neurokinin A in cerebral vessels: characterization, localization and effects in vitroRegulatory Peptides, 20
L. Edvinsson, R. Ekman, P. Goadsby (2010)
Measurement of vasoactive neuropeptides in biological materials: Problems and pitfalls from 30 years of experience and novel future approachesCephalalgia, 30
L. Edvinsson (2017)
The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in MigraineHeadache: The Journal of Head and Face Pain, 57
C. Walker, D. Hay (2013)
CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?British Journal of Pharmacology, 170
S. Aurora, Dw Dodick, C. Turkel, R. DeGryse, S. Silberstein, R. Lipton, H. Diener, MF Brin (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trialCephalalgia, 30
V. Gallai†, P. Sarchielli, A. Floridi, M. Franceschini, M. Codini, G. Glioti, A. Trequattrini, R. Palumbo (1995)
Vasoactive Peptide Levels in The Plasma of Young Migraine Patients With and Without Aura Assessed Both Interictally and IctallyCephalalgia, 15
S. Amara, V. Jonas, M. Rosenfeld, E. Ong, R. Evans (1982)
Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide productsNature, 298
S. Silberstein, R. Lenz, Cen Xu (2015)
Therapeutic Monoclonal Antibodies: What Headache Specialists Need to KnowHeadache: The Journal of Head and Face Pain, 55
J. Hoffmann, P. Goadsby (2012)
New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS InhibitorsCurrent Treatment Options in Neurology, 14
R. Lipton, W. Stewart, S. Diamond, M. Diamond, M. Reed (2001)
Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study IIHeadache: The Journal of Head and Face Pain, 41
Lars Edvinsson, Peter Goadsby (1995)
Neuropeptides in the Cerebral Circulation: Relevance to HeadacheCephalalgia, 15
A. Arimura (1992)
Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of researchRegulatory Peptides, 37
D. Dodick, M. Ashina, J. Brandes, D. Kudrow, M. Lanteri-Minet, V. Osipova, Kerry Palmer, H. Picard, D. Mikol, R. Lenz (2018)
ARISE: A Phase 3 randomized trial of erenumab for episodic migraineCephalalgia, 38
P. Goadsby, L. Edvinsson, R. Ekman (1990)
Vasoactive peptide release in the extracerebral circulation of humans during migraine headacheAnnals of Neurology, 28
T. Ho, K. Connor, Ying Zhang, E. Pearlman, J. Koppenhaver, Xiaoyin Fan, C. Lines, L. Edvinsson, P. Goadsby, D. Michelson (2014)
Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine preventionNeurology, 83
L. Edvinsson (1985)
Functional role of perivascular peptides in the control of cerebral circulationTrends in Neurosciences, 8
M. Bigal, Sarah Walter, A. Rapoport (2015)
Therapeutic antibodies against CGRP or its receptor.British journal of clinical pharmacology, 79 6
H. Diener, Dw Dodick, S. Aurora, C. Turkel, R. DeGryse, R. Lipton, S. Silberstein, MF Brin (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trialCephalalgia, 30
M. Giamberardino, Giannapia Affaitati, P. Martelletti, C. Tana, A. Negro, D. Lapenna, M. Curto, C. Schiavone, L. Stellin, F. Cipollone, R. Costantini (2016)
Impact of migraine on fibromyalgia symptomsThe Journal of Headache and Pain, 17
Wendy Schou, S. Ashina, F. Amin, P. Goadsby, M. Ashina (2017)
Calcitonin gene-related peptide and pain: a systematic reviewThe Journal of Headache and Pain, 18
Ted Miller (2015)
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.Lancet, 386 9995
S. Akerman, P. Goadsby (2015)
Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraineScience Translational Medicine, 7
Z. Hepp, D. Dodick, S. Varon, J. Chia, N. Matthew, P. Gillard, R. Hansen, E. Devine (2016)
Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysisCephalalgia, 37
S. Silberstein, S. Holland, Frederick Freitag, D. Dodick, C. Argoff, E. Ashman (2012)
Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adultsNeurology, 78
Shivang Joshi, Alan Rapoport (2017)
Diclofenac potassium for oral solution (CAMBIA®) in the acute management of a migraine attack: clinical evidence and practical experienceTherapeutic Advances in Neurological Disorders, 10
Walter Stewart, R. Lipton, D. Celentano, Michael Reed (1992)
Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors.JAMA, 267 1
ME Bigal, DW Dodick, AV Krymchantowski, JH VanderPluym, SJ Tepper, E Aycardi, PS Loupe, Y Ma, PJ Goadsby (2016)
TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time pointsNeurology, 87
P. Goadsby, L. Edvinsson, R. Ekman (1988)
Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular systemAnnals of Neurology, 23
Messoud Ashina, David Dodick, Peter Goadsby, Uwe Reuter, Stephen Silberstein, Feng Zhang, Julia Gage, Sunfa Cheng, Daniel Mikol, Robert Lenz (2017)
Erenumab (AMG 334) in episodic migraineNeurology, 89
D. Dodick, P. Goadsby, E. Spierings, J. Scherer, S. Sweeney, D. Grayzel (2014)
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled studyThe Lancet Neurology, 13
SD Silberstein, S Holland, F Freitag, DW Dodick, C Argoff, E Ashman (2012)
Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache SocietyNeurology, 78
E. Cernuda-Morollón, D. Larrosa, C. Ramón, J. Vega, P. Martínez-Camblor, J. Pascual (2013)
Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraineNeurology, 81
R. Uddman, Peter Goadsby, I. Jansen, Lars Edvinsson (1993)
PACAP, a VIP-like Peptide: Immunohistochemical Localization and Effect upon Cat Pial Arteries and Cerebral Blood FlowJournal of Cerebral Blood Flow & Metabolism, 13
A. May, P. Goadsby (2001)
Substance P receptor antagonists in the therapy of migraineExpert Opinion on Investigational Drugs, 10
S. Eftekhari, L. Edvinsson (2011)
Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-levelBMC Neuroscience, 12
Lanfranco Pellesi, S. Guerzoni, L. Pini (2017)
Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to DateClinical Pharmacology in Drug Development, 6
S. Eftekhari, K. Warfvinge, F. Blixt, L. Edvinsson (2013)
Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system.The journal of pain : official journal of the American Pain Society, 14 11
H. Schytz, S. Birk, T. Wienecke, C. Kruuse, J. Olesen, M. Ashina (2009)
PACAP38 induces migraine-like attacks in patients with migraine without aura.Brain : a journal of neurology, 132 Pt 1
R. Lipton, M. Bigal (2005)
Migraine: Epidemiology, Impact, and Risk Factors for ProgressionHeadache: The Journal of Head and Face Pain, 45
R. Uddman, L. Edvinsson (1989)
Neuropeptides in the cerebral circulation.Cerebrovascular and brain metabolism reviews, 1 3
P. Goadsby, P. Holland, M. Martins-Oliveira, J. Hoffmann, C. Schankin, S. Akerman (2017)
Pathophysiology of Migraine: A Disorder of Sensory Processing.Physiological reviews, 97 2
J. Hansen, A. Hauge, J. Olesen, M. Ashina (2010)
Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with auraCephalalgia, 30
M Ashina, D Dodick, PJ Goadsby, U Reuter, S Silberstein, F Zhang, JR Gage, S Cheng, DD Mikol, RA Lenz (2017)
Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label studyNeurology, 89
S. Silberstein, D. Dodick, M. Bigal, P. Yeung, P. Goadsby, Tricia Blankenbiller, M. Grozinski-Wolff, Ronghua Yang, Yuju Ma, E. Aycardi (2017)
Fremanezumab for the Preventive Treatment of Chronic MigraineThe New England Journal of Medicine, 377
L. Edvinsson, P. Emson, J. Mcculloch, K. Tatemoto, R. Uddman (1983)
Neuropeptide Y: Cerebrovascular innervation an vasomotor effects in the catNeuroscience Letters, 43
M. Bigal, D. Dodick, A. Krymchantowski, J. Vanderpluym, S. Tepper, E. Aycardi, P. Loupe, Yuju Ma, P. Goadsby (2016)
TEV-48125 for the preventive treatment of chronic migraineNeurology, 87
R. Uddman, L. Edvinsson, R. Ekman, T. Kingman, J. Mcculloch (1985)
Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: Trigeminal origin and co-existence with substance PNeuroscience Letters, 62
D. Mitsikostas, U. Reuter (2017)
Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studiesCurrent Opinion in Neurology, 30
T. Ho, L. Edvinsson, P. Goadsby (2010)
CGRP and its receptors provide new insights into migraine pathophysiologyNature Reviews Neurology, 6
D. Dodick, P. Goadsby, S. Silberstein, R. Lipton, J. Olesen, M. Ashina, K. Wilks, D. Kudrow, R. Kroll, B. Kohrman, R. Bargar, J. Hirman, Jeffrey Smith (2014)
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trialThe Lancet Neurology, 13
Taketo Yamada (2011)
Therapeutic monoclonal antibodies.The Keio journal of medicine, 60 2
M. Krishna, S. Nadler (2016)
Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune ComplexesFrontiers in Immunology, 7
P. Goadsby, U. Reuter, Y. Hallström, G. Broessner, J. Bonner, Feng Zhang, S. Sapra, H. Picard, D. Mikol, R. Lenz (2017)
A Controlled Trial of Erenumab for Episodic MigraineThe New England Journal of Medicine, 377
Hong Sun, D. Dodick, S. Silberstein, P. Goadsby, U. Reuter, M. Ashina, J. Saper, R. Cady, Y. Chon, J. Dietrich, R. Lenz (2016)
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet Neurology, 15
D. Rossum, U. Hanisch, R. Quirion (1997)
Neuroanatomical Localization, Pharmacological Characterization and Functions of CGRP, Related Peptides and Their ReceptorsNeuroscience & Biobehavioral Reviews, 21
T. Sundrum, C. Walker (2018)
Pituitary adenylate cyclase‐activating polypeptide receptors in the trigeminovascular system: implications for migraineBritish Journal of Pharmacology, 175
L. Edvinsson (2006)
Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks.CNS drug reviews, 11 1
Migraine is a highly prevalent, complex neurological disorder. The burden of disease and the direct/indirect annual costs are enormous. Thus far, treatment options have been inadequate and mostly based on trial and error, leaving a significant unmet need for effective therapies. While the underlying pathophysiology of migraine is incompletely understood, blocking the calcitonin gene-related peptide (CGRP) using monoclonal antibodies targeting CGRP or its receptor and small molecule CGRP receptor antagonists (gepants) have emerged as a promising therapeutic opportunity for the management of migraine. In this review, we discuss new concepts in the pathophysiology of migraine and the role of CGRP, the current guidelines for treating migraine preventively, the medications that are being used, and their limitations. We then discuss small molecule CGRP receptor antagonists, monoclonal antibodies to CGRP ligand and receptor, as well as the detailed results of Phase II and III trials involving these novel treatments. We conclude with a discussion of the implications of blocking CGRP and its receptor.
Drugs – Springer Journals
Published: Jun 4, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.